Skip to main content
Journal ArticleOPEN ACCESS

Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: Does one have advantages over the other?

CNS Spectrums (2018) 23(4) 239-247
DOI: 10.1017/S1092852918001219
21Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

The two approved treatments for tardive dyskinesia both inhibit the vesicular monoamine transporter type 2 (VMAT2) yet have pharmacologic properties that distinguish one from the other. Knowing these differences may help optimize which treatment to select for individual patients.

Cite

CITATION STYLE

APA

Stahl, S. M. (2018). Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: Does one have advantages over the other? CNS Spectrums, 23(4), 239–247. https://doi.org/10.1017/S1092852918001219

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free